Rigel Pharmaceuticals (NASDAQ:RIGL) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
A number of other equities research analysts also recently weighed in on the company. ValuEngine upgraded Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Rigel Pharmaceuticals in a report on Friday, February 2nd. Piper Jaffray Companies restated an “overweight” rating and set a $6.00 price objective on shares of Rigel Pharmaceuticals in a report on Thursday, December 21st. Cantor Fitzgerald assumed coverage on Rigel Pharmaceuticals in a report on Thursday, December 14th. They set an “overweight” rating and a $6.00 price objective for the company. Finally, Zacks Investment Research upgraded Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a report on Saturday, November 11th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $5.54.
Shares of Rigel Pharmaceuticals (RIGL) traded down $0.03 during mid-day trading on Thursday, reaching $3.79. The company’s stock had a trading volume of 1,719,566 shares, compared to its average volume of 1,330,000. The company has a market capitalization of $555.20, a P/E ratio of -6.42 and a beta of 1.29. Rigel Pharmaceuticals has a 1-year low of $2.14 and a 1-year high of $4.71.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.